PUBLISHER: TechNavio | PRODUCT CODE: 1908808
PUBLISHER: TechNavio | PRODUCT CODE: 1908808
The global erythropoietin stimulating agents market is forecasted to grow by USD 5355.8 mn during 2025-2030, accelerating at a CAGR of 8.7% during the forecast period. The report on the global erythropoietin stimulating agents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by escalating burden of chronic kidney diseases, expanding landscape of oncology and chemotherapy induced anemia, proliferation of specialized renal care and dialysis centers.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2026 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 8.2% |
| CAGR | 8.7% |
| Incremental Value | $5355.8 mn |
Technavio's global erythropoietin stimulating agents market is segmented as below:
By Type
By Indication
By End-User
Geography
This study identifies the ascendancy of long-acting formulations and patient centric dosing regimens as one of the prime reasons driving the global erythropoietin stimulating agents market growth during the next few years. Also, maturation of biosimilar sector from entry to ecosystem dominance and paradigm shift toward personalized anemia management and conservative dosing will lead to sizable demand in the market.
The report on the global erythropoietin stimulating agents market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global erythropoietin stimulating agents market vendors that include Akebia Therapeutics, Amgen Inc., Biocon Ltd., Biosidus SA, Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson Services, Kyowa Kirin Co. Ltd., LG Chem Ltd., Nanogen Pharmaceuticals, Novartis AG, Pfizer Inc., Reliance Industries Ltd., Sandoz Group AG, STADA Arzneimittel AG, Teva Pharmaceutical Ltd., Zydus Lifesciences Ltd.. Also, the global erythropoietin stimulating agents market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.